IL90069A - השימוש ב-31 ציס חומצה רטינואית להכנת תרופה לטיפול בחטטת קונגלובטיתונודולוציסטית - Google Patents
השימוש ב-31 ציס חומצה רטינואית להכנת תרופה לטיפול בחטטת קונגלובטיתונודולוציסטיתInfo
- Publication number
- IL90069A IL90069A IL9006989A IL9006989A IL90069A IL 90069 A IL90069 A IL 90069A IL 9006989 A IL9006989 A IL 9006989A IL 9006989 A IL9006989 A IL 9006989A IL 90069 A IL90069 A IL 90069A
- Authority
- IL
- Israel
- Prior art keywords
- retinoic acid
- cis
- acne
- months
- weeks
- Prior art date
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 51
- 229960005280 isotretinoin Drugs 0.000 title claims abstract description 51
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 49
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 title claims abstract description 49
- 239000003814 drug Substances 0.000 title claims description 18
- 230000037396 body weight Effects 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 238000011282 treatment Methods 0.000 claims description 38
- 150000001875 compounds Chemical class 0.000 claims description 16
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 229940088710 antibiotic agent Drugs 0.000 claims description 6
- -1 13-cis-retinoic acid compound Chemical class 0.000 claims description 4
- 229940011871 estrogen Drugs 0.000 claims description 4
- 239000000262 estrogen Substances 0.000 claims description 4
- 239000004098 Tetracycline Substances 0.000 claims description 3
- 229960002180 tetracycline Drugs 0.000 claims description 3
- 229930101283 tetracycline Natural products 0.000 claims description 3
- 235000019364 tetracycline Nutrition 0.000 claims description 3
- 150000003522 tetracyclines Chemical class 0.000 claims description 3
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 claims description 2
- 229960000860 dapsone Drugs 0.000 claims description 2
- 229960004618 prednisone Drugs 0.000 claims description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000004797 therapeutic response Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 description 19
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 18
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 18
- 229930002330 retinoic acid Natural products 0.000 description 17
- 230000000694 effects Effects 0.000 description 13
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 12
- 206010000503 Acne cystic Diseases 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 229960001727 tretinoin Drugs 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 235000019155 vitamin A Nutrition 0.000 description 10
- 239000011719 vitamin A Substances 0.000 description 10
- 229940045997 vitamin a Drugs 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 6
- 230000007059 acute toxicity Effects 0.000 description 5
- 231100000403 acute toxicity Toxicity 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 208000031513 cyst Diseases 0.000 description 5
- 238000009533 lab test Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 229960003471 retinol Drugs 0.000 description 4
- 235000020944 retinol Nutrition 0.000 description 4
- 239000011607 retinol Substances 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 239000004342 Benzoyl peroxide Substances 0.000 description 3
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 206010043275 Teratogenicity Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 235000019400 benzoyl peroxide Nutrition 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 231100000211 teratogenicity Toxicity 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 208000034577 Benign intracranial hypertension Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 150000001299 aldehydes Chemical group 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 201000006122 hypervitaminosis A Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229940127249 oral antibiotic Drugs 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 208000001381 pseudotumor cerebri Diseases 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 150000002266 vitamin A derivatives Chemical class 0.000 description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- NCYCYZXNIZJOKI-HWCYFHEPSA-N 13-cis-retinal Chemical compound O=C/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-HWCYFHEPSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 201000010183 Papilledema Diseases 0.000 description 1
- 206010033712 Papilloedema Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 231100000269 corneal opacity Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 230000009433 disease-worsening effect Effects 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 231100000380 osteotoxicity Toxicity 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000589 photocarcinogenesis Toxicity 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000011268 retreatment Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18626088A | 1988-04-26 | 1988-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL90069A true IL90069A (he) | 1994-04-12 |
Family
ID=22684246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9006989A IL90069A (he) | 1988-04-26 | 1989-04-24 | השימוש ב-31 ציס חומצה רטינואית להכנת תרופה לטיפול בחטטת קונגלובטיתונודולוציסטית |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5698593A (he) |
| EP (1) | EP0414772B1 (he) |
| AT (1) | ATE135909T1 (he) |
| AU (1) | AU627733B2 (he) |
| DE (1) | DE68926115T2 (he) |
| IL (1) | IL90069A (he) |
| WO (1) | WO1989010128A1 (he) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7452545B2 (en) * | 2001-11-13 | 2008-11-18 | Yu Ruey J | Oligosaccharide aldonic acids and their topical use |
| US6720001B2 (en) * | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| US6339107B1 (en) | 2000-08-02 | 2002-01-15 | Syntex (U.S.A.) Llc | Methods for treatment of Emphysema using 13-cis retinoic acid |
| US20030215493A1 (en) * | 2002-04-30 | 2003-11-20 | Patel Pravin M. | Composition and method for dermatological treatment |
| US20110142922A1 (en) * | 2002-04-30 | 2011-06-16 | Ferndale Ip, Inc. | Stabilized composition and method for dermatological treatment |
| ES2290682T3 (es) * | 2004-03-10 | 2008-02-16 | SAERTEX GMBH & CO. KG | Complejo multiaxial. |
| US8722650B1 (en) | 2005-06-24 | 2014-05-13 | Medicis Pharmaceutical Corporation | Extended-release minocycline dosage forms |
| US20080242642A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US8252776B2 (en) * | 2007-04-02 | 2012-08-28 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| EP1971331A2 (en) * | 2005-12-09 | 2008-09-24 | Basilea Pharmaceutica AG | 4-oxo-(iso)tretinoin for the topical treatment of severe dermatological disorders |
| US20070254858A1 (en) * | 2006-04-27 | 2007-11-01 | Cronk Peter J | Contraceptive and Acne Medication Combination and Treatment of Acne and Other Diseases with Reduced Side Effects |
| US20070254025A1 (en) * | 2006-04-27 | 2007-11-01 | Cronk Peter J | Oral contraceptive and acne medication combination and treatment of acne with reduced side effects |
| WO2010017310A1 (en) | 2008-08-06 | 2010-02-11 | Medicis Pharmaceutical Corporation | Method for the treatment of acne and certain dosage forms thereof |
| US9561241B1 (en) | 2011-06-28 | 2017-02-07 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for minocycline |
| US9023399B2 (en) | 2012-11-16 | 2015-05-05 | NU Technology, LLC | Water-soluble anti-inflammatory cream with natural ingredients base |
| US8613961B1 (en) | 2013-01-09 | 2013-12-24 | NU Technology, LLC | Dermatological cream with natural ingredients base |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3729568A (en) * | 1969-09-23 | 1973-04-24 | Johnson & Johnson | Acne treatment |
| US3882244A (en) * | 1971-12-13 | 1975-05-06 | Univ California | Method of treating acne with a c{hd 20 {b acid |
| US3932665A (en) * | 1974-04-05 | 1976-01-13 | Scott Eugene J Van | Process for the treatment of acne vulgaris utilizing retinal |
| US3934028A (en) * | 1974-04-22 | 1976-01-20 | The Regents Of The University Of California | Acne and psoriasis treatment with retinoic acid analogs |
| US4322438A (en) * | 1979-08-06 | 1982-03-30 | United States Of America | Method for the use of orally administered 13-cis-retinoic acid in the treatment of acne |
| US4487782A (en) * | 1982-03-26 | 1984-12-11 | Ortho Pharmaceutical Corporation | Topical treatment of non-inflammatory acne |
| CH658387A5 (de) * | 1984-04-02 | 1986-11-14 | Hoffmann La Roche | Pharmazeutische praeparate. |
| US4545977A (en) * | 1985-01-11 | 1985-10-08 | G. D. Searle & Co. | Compositions and methods for treating severe acne with isotretinoin |
| US4677120A (en) * | 1985-07-31 | 1987-06-30 | Molecular Design International | Topical prodrugs for treatment of acne and skin diseases |
-
1989
- 1989-04-24 IL IL9006989A patent/IL90069A/he unknown
- 1989-04-26 EP EP89905844A patent/EP0414772B1/en not_active Expired - Lifetime
- 1989-04-26 AU AU35690/89A patent/AU627733B2/en not_active Ceased
- 1989-04-26 WO PCT/US1989/001752 patent/WO1989010128A1/en active IP Right Grant
- 1989-04-26 DE DE68926115T patent/DE68926115T2/de not_active Expired - Fee Related
- 1989-04-26 AT AT89905844T patent/ATE135909T1/de not_active IP Right Cessation
-
1993
- 1993-04-15 US US08/047,007 patent/US5698593A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0414772A4 (en) | 1991-07-03 |
| DE68926115D1 (de) | 1996-05-02 |
| EP0414772A1 (en) | 1991-03-06 |
| AU627733B2 (en) | 1992-09-03 |
| AU3569089A (en) | 1989-11-24 |
| ATE135909T1 (de) | 1996-04-15 |
| EP0414772B1 (en) | 1996-03-27 |
| US5698593A (en) | 1997-12-16 |
| DE68926115T2 (de) | 1996-10-02 |
| WO1989010128A1 (en) | 1989-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5698593A (en) | Method for treating acne | |
| DE69821624T2 (de) | 9-cis-RETINSÄURE FÜR ZELLVERMITTELTE IMMUNKRANKHEITEN | |
| EP0308210B1 (en) | Topical treatment of diseased skin disorders | |
| Strauss et al. | Effect of cyclic progestin-estrogen therapy on sebum and acne in women | |
| US4322438A (en) | Method for the use of orally administered 13-cis-retinoic acid in the treatment of acne | |
| DE60117046T2 (de) | Kombination von fenofibrat und von coenzym q10 für die behandlung der endothelial- missfunktion | |
| Bartholomew et al. | Oxytetracycline in the treatment of ocular rosacea: a double-blind trial. | |
| Shalita | Mucocutaneous and systemic toxicity of retinoids: monitoring and management | |
| US20100087403A1 (en) | Topical treatment of skin infection | |
| US3934028A (en) | Acne and psoriasis treatment with retinoic acid analogs | |
| US4021573A (en) | Psoriasis treatment with retinoic acid analogs | |
| US4588750A (en) | Therapeutic compositions for reducing sebum secretion | |
| Burge et al. | The efficacy of an aromatic retinoid, Tigason (etretinate), in the treatment of Darier's disease | |
| Cochran et al. | Topical zinc therapy for acne vulgaris | |
| Lowe et al. | Systemic retinoid therapy for psoriasis | |
| JPH04243825A (ja) | 色素沈着症治療剤 | |
| US5667790A (en) | Aluminum chlorhydrate as a treatment for acne and rosacea | |
| US3072527A (en) | Use of tolbutamide in the treatment of acne | |
| US4252797A (en) | Corticosteroid calcium compositions and treatment of rheumatic diseases therewith | |
| EP0114003A1 (en) | Antiandrogen and antibiotic treatment of acne and pharmaceutical preparations therefor | |
| PT1100490E (pt) | Tratamento do acne e do fotoenvelhecimento por contacto de curta duração com retinóides tópicos | |
| Christiansen et al. | Etretinate (Tigason®) and Betamethasone Valerate (Celeston Valerate®) in the Treatment of Psoriasis: A Double-Blind, Randomized, Multicenter Trial | |
| WO2003022292A1 (fr) | Formulation pharmaceutique orale contenant du charbon actif et utilisation de cette formulation | |
| WO1983000628A1 (en) | A method of treating acne vulgaris and composition containing carbamide peroxide | |
| Baur et al. | Current concepts in the pathogenesis and treatment of acne |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |